(USD) | Mar 2024 | Q/Q |
---|---|---|
Revenue | 2.2B | -1% |
Gross Profit | 1.5B | - |
Cost Of Revenue | 643MM | -12% |
Operating Income | 747MM | +15% |
Operating Expenses | 800MM | - |
Net Income | 599MM | +14% |
R&D | 162MM | -7% |
G&A | 547MM | -3% |
Amortization | 44MM | - |
Interest Expense | 58MM | -2% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Zacks.com users have recently been watching Zoetis (ZTS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zoetis Inc. (NYSE:ZTS) Q1 2024 Earnings Call Transcript May 2, 2024 Zoetis Inc. beats earnings expectations. Reported EPS is $1.38, expectations were $1.35. Zoetis Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the First Quarter 2024 Financial […]
ZTS earnings call for the period ending March 31, 2024.
Zoetis ( NYSE:ZTS ) First Quarter 2024 Results Key Financial Results Revenue: US$2.19b (up 9.5% from 1Q 2023). Net...
Explore how Zoetis Inc (ZTS) achieved significant operational growth and navigated market complexities in the first quarter of 2024.
Unveiling the Financial and Strategic Position of Zoetis Inc (ZTS)
Q1 2024 Zoetis Inc Earnings Call
An estimates-beating quarter and raised guidance made the company a pet stock for many investors.
Zoetis stock reversed its recent bad fortune Thursday, rising after the pet-drug maker beat first-quarter expectations.
The animal health firm has had a tough year. Shares have plunged in response to negative media reports about an important new medicine.